Accordingly, when leptin activity was inhibited by using the full leptin receptor antagonist, the peptide LDFI [31], both Tsg101 expression and the amount of exosomes released by leptin-treated breast cancer cells were reduced. This evidence concerns the gene LEP and breast carcinoma.